145 filings
Page 6 of 8
8-K
t5q7efsdw74ugg 905b
7 May 20
Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update
6:18am
DEFA14A
jt90biw7u7nzot5
29 Apr 20
Additional proxy soliciting materials
4:02pm
DEF 14A
n2nd9 h4hsh8zjze6
29 Apr 20
Definitive proxy
4:00pm
8-K
j8gqn
28 Apr 20
Karuna Therapeutics Appoints Christopher J. Coughlin to its
6:13am
S-8
f1s00rufaws22vu
24 Mar 20
Registration of securities for employees
4:02pm
10-K
q2p5y
24 Mar 20
Annual report
6:32am
8-K
jecgk4js 4z81i
24 Mar 20
Karuna Therapeutics Reports Fourth Quarter and Year End 2019 Financial
6:13am
8-K
pvl91ugyqcwh577lb
2 Dec 19
Departure of Directors or Certain Officers
4:01pm
8-K
r734yuoxup jd3m8ahh
21 Nov 19
Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock
4:05pm
424B4
j87xki qn
21 Nov 19
Prospectus supplement with pricing info
4:02pm
EFFECT
9j3dw1a9zqg 8q0aeg0
21 Nov 19
Notice of effectiveness
12:15am
8-K
erwqcq
18 Nov 19
Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
6:04am
CORRESP
4wqgh kkel
18 Nov 19
Correspondence with SEC
12:00am
CORRESP
qjb31 tuw0
18 Nov 19
Correspondence with SEC
12:00am
8-K
cvpa0 29m389rtn
7 Nov 19
Karuna Therapeutics Reports Third Quarter 2019 Financial Results and Provides General Business Update
6:04am
UPLOAD
admc364vyn
5 Nov 19
Letter from SEC
12:00am
DRS
nbct8zmpvge eq9
28 Oct 19
Draft registration statement
12:00am